Sheba Medical Center and Roche Partner to Revolutionize NSCLC Diagnostics with AI-Powered Solutions
The collaboration between ARC Innovation and Roche centers on integrating artificial intelligence algorithms with Roche’s navify® Digital Pathology platform to streamline the detection of molecular markers in NSCLC. This integration could significantly reduce the time between diagnosis and treatment initiation, potentially improving patient outcomes through faster access to appropriate therapies.
“This collaboration marks an exciting moment in our efforts to transform healthcare on a global scale,” says Prof. Yitshak Kreiss, Director General of Sheba Medical Center. “When one of the world’s leading digital pathology providers teams up with Sheba’s leading innovators in AI-driven diagnostics, it’s not just a statement of intent; it’s the start of a groundbreaking journey. Together, we will be able to advance patient care in ways that were previously unimaginable. This collaboration will help us leverage advanced technologies to create new benchmarks for diagnostic accuracy and treatment efficacy.”
Looking ahead, the implications of this partnership extend beyond immediate applications in NSCLC diagnostics. Prof. Eyal Zimlichman, Chief Innovation Officer at Sheba Medical Center, outlines the broader vision: “The technologies we will develop together can completely transform diagnostic processes, reducing delays and ensuring that patients get the right treatment at the right time. This initiative is not just about innovation; it’s about making a real difference in the lives of patients battling cancer.”
Sheba & Roche Leverage Combined Expertise
The initiative will leverage Sheba’s expertise in digital pathology alongside Roche’s clinical decision support capabilities to develop integrated algorithms that not only identify biomarkers but also predict treatment response patterns. While initially focused on NSCLC, the partners envision expanding these technological advances to other cancer types and diseases in the future.
Prof. Iris Barshack, Director of Sheba’s Pathology Institute, emphasizes the innovative aspect of the collaboration: “We are proud to be at the forefront of developing a comprehensive new approach that integrates cutting-edge AI algorithms for diagnosing NSCLC within Roche’s navify® Digital Pathology open innovation platform. By working together with Roche, we are setting the stage to change the standard of care for NSCLC and potentially for other cancers as well.”
The partnership represents a significant step forward in personalized medicine, combining Sheba’s clinical expertise with Roche’s technological capabilities. This collaboration could potentially revolutionize how healthcare providers approach cancer diagnostics and treatment planning.
“I am excited to embark on this strategic collaboration with Sheba-ARC and the Pathology Institute in the Digital Pathology space,” states Netanel Amichai, GM of Roche Israel. “This collaboration lays a strong foundation for future innovation, serving as a platform to expand our joint efforts into other key innovative areas such as oncology, genomics and personalized medicine.”
Setting New Standards in Oncology Care
Michael Rivers, VP and Lifecycle Leader of Roche Digital Pathology, emphasizes the collaboration’s potential: “We are thrilled to work with Sheba Medical Center and Prof. Iris Barshack, who is renowned for her leadership in digital pathology. Together, we aim to demonstrate how advanced digital and AI technologies can significantly improve diagnostic accuracy and patient care. This collaboration provides the framework for the first of potentially many impactful projects designed to highlight the transformative benefits of digital pathology and innovative AI image analysis tools on cancer diagnosis and patient care.”
This collaboration represents a significant milestone in the advancement of digital pathology and personalized medicine, potentially setting new standards for diagnostic accuracy and treatment efficacy in oncology care. As the partnership progresses, the healthcare industry will be watching closely to see how these innovations reshape the landscape of cancer diagnostics and treatment.
More Posts
Sheba’s Physicians Sweep Forbes Israel’s 2025 “Best Doctors” List
Forbes Israel has named an exceptional number of Sheba Medical Center’s physicians on its 2025 “Best Doctors” list. Earlier this year, Sheba was ranked by Newsweek as one of the World’s Top 10 Hospitals. This recognition and alignment between institutional and individual excellence signals to the global medical community that Sheba concentrates many of Israel’s most trusted clinical leaders under one roof.
Twinning and Training: Scalable Solutions for Global Eye Cancer Equity
Sheba Global Ophthalmology (SGO) demonstrates how sustainable twinning and hands-on training create self-reliant ocular oncology capacity in low- and middle-income countries (LMICs), far surpassing the limitations of short-term outreach.
ARC Launches HaMeirim: Sheba’s New Cardiovascular Innovation Center
Sheba Medical Center’s ARC innovation arm has launched and inaugurated HaMeirim – ARC Cardiovascular (“The Radiant Ones” or “Those who shine”), a dedicated innovation center for the Heart, Thorax, and Vascular Center.
